Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial

Research output: Contribution to journal › Journal article › Research › peer-review

  • Klaus Rasmussen
  • Michael Maeng
  • Anne Kaltoft
  • Per Thayssen
  • Henning Kelbaek
  • Hans Henrik Tilsted
  • Ulrik Abildgaard
  • Evald Høj Christiansen
  • Engstrøm, Thomas
  • Lars Romer Krusell
  • Jan Ravkilde
  • Hansen, Peter Riis
  • Knud Nørregaard Hansen
  • Steen Zabell Abildstrøm
  • Jens Aarøe
  • Jan Skov Jensen
  • Steen Dalby Kristensen
  • Hans Erik Bøtker
  • Morten Madsen
  • Søren Paaske Johnsen
  • Lisette Okkels Jensen
  • Henrik Toft Sørensen
  • Leif Thuesen
  • Jens Flensted Lassen
  • SORT OUT III study group
In low-risk patients, the zotarolimus-eluting stent has been shown to reduce rates of restenosis without increasing the risk of stent thrombosis. We compared the efficacy and safety of the zotarolimus-eluting stent versus the sirolimus-eluting stent in patients with coronary artery disease who were receiving routine clinical care with no direct follow-up.
Original languageEnglish
JournalLancet
Volume375
Issue number9720
Pages (from-to)1090-9
Number of pages10
ISSN0140-6736
DOIs
Publication statusPublished - 27 Mar 2010

ID: 34077476